NCT01948297View on ClinicalTrials.gov

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

PHASE1TerminatedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 26, 2020

Study Completion Date

June 26, 2020

Conditions
Solid Tumours
Interventions
DRUG

Debio1347 (CH5183284)

Debio1347 (CH5183284) tablets for oral administration

Trial Locations (8)

10065

Memorial Sloan-Kettering Hospital, New York

11031

Taipei Medical University Hospital, Taipei

169610

National Cancer Center Singapore, Singapore

02114

Dana-Farber Cancer Institute, Boston

02215

Massachusetts General Hospital, Boston

77030-4009

The University of Texas; MD Anderson Cancer Center, Houston

03080

Seoul National University Hospital, Seoul

Unknown

Vall d'Hebron University Hospital, Barcelona

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY